Mayo Clinic has had a long-standing commitment to support and lead NCTN clinical trials through NCCTG, ECOG, ACOSOG, ACRIN, RTOG, and GOG. Mayo Clinic served as the founding institution and operational base for NCCTG until its merger with CALGB and ACOSOG to form the Alliance. Mayo investigators have also had leadership roles in these groups as well as in the newly forming groups (Alliance, ECOG-ACRIN, and NRG). The current clinical research structure within the Mayo Clinic Cancer Center (MCCC) continues to prioritize NIH sponsored trial, including NCTN trials, over other trials. Support systems are in place within the MCCC to maximize accrual and to support the translational components of these trials, including biospecimen collection and imaging. Mayo investigators also remained very active in trial leadership. Mayo investigators have also been very effective in utilizing data and biospecimens collected from NCTN trials to address important and relevant research questions. Through this commitment to research, Mayo investigators have published multiple reports in high impact journals and successfully obtained multiple grants, including R01 grants, to support this work.
The U10 Network Lead Academic Participating Site Grant provides the infrastructure support to perform NCTN clinical trials at Mayo Clinic and the activities related to our participation in the NCTN groups Alliance, ECOG-ACRIN, and NRG. Mayo Clinic intends to remain one of the leading sites in accrual to NCTN clinical trials as well as to continue in key leadership and scientific roles in the NCTN member groups. The ultimate goal is to relieve the burdens of illness in patients with cancer through potentially practice changing trials.
|Yoon, Harry H; Tougeron, David; Shi, Qian et al. (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033-43|
|Huang, Jocelin; Nair, Suresh G; Mahoney, Michelle R et al. (2014) Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer 13:100-9|
|Gonsalves, Wilson I; Mahoney, Michelle R; Sargent, Daniel J et al. (2014) Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 106:|
|Lee, Adam M; Shi, Qian; Pavey, Emily et al. (2014) DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst 106:|
|Renfro, Lindsay A; Grothey, Axel; Xue, Yuan et al. (2014) ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. J Natl Cancer Inst 106:|
|Boughey, Judy C; McCall, Linda M; Ballman, Karla V et al. (2014) Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg 260:608-14; discussion 614-6|